磁共振成像时代前列腺特异性抗原密度检测临床显著前列腺癌的诊断性能:系统综述与荟萃分析
该系统综述与荟萃分析纳入39项研究,评估前列腺活检前接受磁共振成像(MRI)患者中前列腺特异性抗原密度(PSAD)对临床显著前列腺癌(CSPCa)的诊断性能。在MRI阳性、MRI阴性和PI-RADS/Likert 3分病变患者中,不同PSAD阈值的汇总敏感度和特异度被量化;MRI阴性且PSAD<0.15 ng/ml/ml时CSPCa验后概率为6%,PSAD<0.10 ng/ml/ml时降至4%。作者认为PSAD与MRI联合具有互补的诊断性能和预测价值,将PSAD纳入活检决策可能改善风险调整后的诊疗。
要点
- MRI阳性患者中,PSAD 0.1、0.15、0.2 ng/ml/ml的汇总敏感度分别为0.87、0.74、0.51,特异度分别为0.35、0.61、0.81。
- MRI阴性患者中,PSAD 0.1、0.15、0.2 ng/ml/ml的汇总敏感度分别为0.85、0.60、0.33,特异度分别为0.36、0.66、0.84。
- MRI阴性患者PSAD<0.15 ng/ml/ml时CSPCa验后概率为6%,PSAD<0.10 ng/ml/ml时降至4%。
核心结论
- 该系统综述定量评估了PSAD联合前列腺MRI对CSPCa的诊断性能,显示二者具有互补的诊断性能和预测价值,尤其在MRI阴性及PI-RADS 3或Likert 3分病变患者中。
- 作者认为将PSAD纳入前列腺活检决策可能改善风险调整后的诊疗。
研究设计与样本
- 两位研究者按照PRISMA标准进行系统综述,检索PubMed、Scopus和Embase,共识别1536篇论文,详细审阅248篇,最终纳入39项符合条件的研究。
- 纳入研究发表于2012年1月1日至2021年12月31日,报告PSAD对接受活检前前列腺MRI及后续前列腺活检男性的CSPCa诊断性能,以活检病理为金标准。
主要发现
- MRI阳性患者中,PSAD 0.1 ng/ml/ml的汇总敏感度为0.87、特异度为0.35;PSAD 0.15 ng/ml/ml为0.74和0.61;PSAD 0.2 ng/ml/ml为0.51和0.81。
- MRI阴性患者中,PSAD 0.1 ng/ml/ml的汇总敏感度为0.85、特异度为0.36;PSAD 0.15 ng/ml/ml为0.60和0.66;PSAD 0.2 ng/ml/ml为0.33和0.84。
- PI-RADS 3或Likert 3分病变患者中,PSAD 0.1 ng/ml/ml的汇总敏感度为0.87、特异度为0.39;PSAD 0.15 ng/ml/ml为0.61和0.69;PSAD 0.2 ng/ml/ml为0.42和0.82。
- MRI阴性患者中,PSAD<0.15 ng/ml/ml时CSPCa验后概率为6%,PSAD<0.10 ng/ml/ml时降至4%。
关键数值与推荐
- MRI阳性患者:PSAD 0.1 ng/ml/ml汇总敏感度0.87、特异度0.35;PSAD 0.15 ng/ml/ml为0.74和0.61;PSAD 0.2 ng/ml/ml为0.51和0.81。
- MRI阴性患者:PSAD 0.1 ng/ml/ml汇总敏感度0.85、特异度0.36;PSAD 0.15 ng/ml/ml为0.60和0.66;PSAD 0.2 ng/ml/ml为0.33和0.84。
- PI-RADS 3或Likert 3分病变患者:PSAD 0.1 ng/ml/ml汇总敏感度0.87、特异度0.39;PSAD 0.15 ng/ml/ml为0.61和0.69;PSAD 0.2 ng/ml/ml为0.42和0.82。
- MRI阴性患者PSAD<0.15 ng/ml/ml时CSPCa验后概率为6%,PSAD<0.10 ng/ml/ml时为4%。
临床怎么用
- 作者认为将PSAD纳入前列腺活检决策可能改善风险调整后的诊疗。
- 作者指出MRI阴性或PI-RADS(Likert)3分病变患者若PSAD<0.10 ng/ml/ml,CSPCa概率很低(分别为4%或6%),可能降低这些患者的活检需求。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: There has been a dramatic increase in the use of prostate magnetic resonance imaging (MRI) in the diagnostic workup. With prostate volume calculated from MRI, prostate-specific antigen density (PSAD) now is a ready-to-use parameter for prostate cancer (PCa) risk stratification before prostate biopsy, especially among patients with negative MRI or equivocal lesions. OBJECTIVE: In this review, we aimed to evaluate the diagnostic performance of PSAD for clinically significant prostate cancer (CSPCa) among patients who received MRI before prostate biopsy. EVIDENCE ACQUISITION: Two investigators performed a systematic review according of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria. Studies (published between January 1, 2012, and December 31, 2021) reporting the diagnostic performance (outcomes) of PSAD (intervention) for CSPCa among men who received prebiopsy prostate MRI and subsequent prostate biopsy (patients), using biopsy pathology as the gold standard (comparison), were eligible for inclusion. EVIDENCE SYNTHESIS: A total of 1536 papers were identified in PubMed, Scopus, and Embase. Of these, 248 studies were reviewed in detail and 39 were qualified. The pooled sensitivity (SENS) and specificity (SPEC) for diagnosing CSPCa among patients with positive MRI were, respectively, 0.87 and 0.35 for PSAD of 0.1 ng/ml/ml, 0.74 and 0.61 for PSAD of 0.15 ng/ml/ml, and 0.51 and 0.81 for PSAD of 0.2 ng/ml/ml. The pooled SENS and SPEC for diagnosing CSPCa among patients with negative MRI were, respectively, 0.85 and 0.36 for PSAD of 0.1 ng/ml/ml, 0.60 and 0.66 for PSAD of 0.15 ng/ml/ml, and 0.33 and 0.84 for PSAD of 0.2 ng/ml/ml. The pooled SENS and SPEC among patients with Prostate Imaging Reporting and Data System (PI-RADS) 3 or Likert 3 lesions were, respectively, 0.87 and 0.39 for PSAD of 0.1 ng/ml/ml, 0.61 and 0.69 for PSAD of 0.15 ng/ml/ml, and 0.42 and 0.82 for PSAD of 0.2 ng/ml/ml. The post-test probability for CSPCa among patients with negative MRI was 6% if PSAD was <0.15 ng/ml/ml and dropped to 4% if PSAD was <0.10 ng/ml/ml. CONCLUSIONS: In this systematic review, we quantitatively evaluated the diagnosis performance of PSAD for CSPCa in combination with prostate MRI. It demonstrated a complementary performance and predictive value, especially among patients with negative MRI and PI-RADS 3 or Likert 3 lesions. Integration of PSAD into decision-making for prostate biopsy may facilitate improved risk-adjusted care. PATIENT SUMMARY: Prostate-specific antigen density is a ready-to-use parameter in the era of increased magnetic resonance imaging (MRI) use in clinically significant prostate cancer (CSPCa) diagnosis. Findings suggest that the chance of having CSPCa was very low (4% or 6% for those with negative prebiopsy MRI or Prostate Imaging Reporting and Data System (Likert) score 3 lesion, respectively, if the PSAD was <0.10 ng/ml/ml), which may lower the need for biopsy in these patients.
引用
- Wang S, Kozarek J, Russell R, et al. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2023. PMID: 37640584. doi:10.1016/j.euo.2023.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。